Contrast performance best with zero spherical aberrations

Article

By using adaptive optics and physiological eye models, Pablo Artal and colleagues from Universidad de Murcia, Spain have determined that contrast performance peaks when spherical aberration is completely corrected.

By using adaptive optics and physiological eye models, Pablo Artal and colleagues from Universidad de Murcia, Spain have determined that contrast performance peaks when spherical aberration is completely corrected.

An adaptive-optics based vision simulator that allowed for simultaneous manipulation of ocular wavefront aberration and measurement of visual performance was created. The simulator consisted of a wavefront sensor, an adaptive optics mirror and a visual testing path. Subjective measurements of contrast sensitivity in five subjects with different levels of naturally occurring spherical aberration, at 15 c/deg with a 4.8 mm pupil, were performed.

Contrast sensitivity was measured for spherical aberration values of -0.09, 0.0, 0.09 and 0.182 µm with the other naturally occurring aberrations of the eye present and corrected and with defocus varying from +0.5 to -0.5 D. The same levels of spherical aberration were compared in physiological eye models to establish tolerances to tilt and decentration and to verify through-focus performance.

Each subject experienced peak contrast sensitivity performance with varying levels of spherical aberration when their natural aberrations were present, however, the average contrast performance peaked with 0 µm of spherical aberration.

The researchers concluded that contrast performance is at its best when spherical aberration is completely corrected.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.